Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9HCF6
UPID:
TRPM3_HUMAN
Alternative names:
Long transient receptor potential channel 3; Melastatin-2
Alternative UPACC:
Q9HCF6; A2A3F6; A9Z1Y7; Q5VW02; Q5VW03; Q5VW04; Q5W5T7; Q86SH0; Q86SH6; Q86UL0; Q86WK1; Q86WK2; Q86WK3; Q86WK4; Q86YZ9; Q86Z00; Q86Z01; Q9H0X2
Background:
Transient receptor potential cation channel subfamily M member 3 (TRPM3), also known as Long transient receptor potential channel 3 and Melastatin-2, plays a pivotal role in calcium ion entry. Its activity is modulated by various factors including extracellular osmolarity, store depletion, and muscarinic receptor activation. TRPM3 forms heteromultimeric ion channels with TRPM1, facilitating the permeation of calcium and zinc ions.
Therapeutic significance:
TRPM3 is implicated in neurodevelopmental disorders characterized by hypotonia, dysmorphic facies, and skeletal anomalies, with or without seizures, and in Cataract 50 with or without glaucoma. These associations highlight its potential as a target for therapeutic intervention in these conditions.